A drug company’s risk of receiving a promotion enforcement letter from the US Food and Drug Administration may increase with corporate mergers and acquisitions and a failure to clear away old advertising campaigns.
Drug Promotion: M&A, Old Social Media Posts Can Increase Risk Of US FDA Enforcement
The loss of institutional knowledge about OPDP’s prior comments on promotional materials can result in an enforcement letter for the new owner of a company or product, experts say.
